{"id":"NCT02208297","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","officialTitle":"Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2014-08-05","resultsPosted":"2020-09-03","lastUpdate":"2020-09-25"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation","Pain","Cataract"],"interventions":[{"type":"DRUG","name":"Loteprednol Etabonate Gel (BID)","otherNames":["Lotemax"]},{"type":"DRUG","name":"Vehicle Gel (BID)","otherNames":["Vehicle"]}],"arms":[{"label":"Loteprednol Etabonate Gel (BID)","type":"EXPERIMENTAL"},{"label":"Vehicle Gel (BID)","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)","primaryOutcome":{"measure":"Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells","timeFrame":"8 days","effectByArm":[{"arm":"Loteprednol Etabonate Gel (BID)","deltaMin":38,"sd":null},{"arm":"Vehicle Gel (BID)","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":162},"commonTop":[]}}